Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 3/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 9/20 | 0.47 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | POLG | P54098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9128050 | 0.99 | TGM2 (0.51) | TGM2NT5EKRASSTING1FUT5 | |
| SCHEMBL9124928 | 0.92 | NT5E (0.53) | TGM2NT5EKRASSTING1POLB | |
| Guanosine SCHEMBL4326691 | 0.86 | TGM2 (0.58) | TGM2NT5EKRASFUT5 | |
| Guanosine SCHEMBL16371097 | 0.86 | TGM2 (0.58) | TGM2NT5EKRASFUT5 | |
| SCHEMBL5861503 | 0.84 | NT5E (0.60) | TGM2NT5EKRASSTING1FUT5 | |
| SCHEMBL4081026 | 0.84 | NT5E (0.60) | TGM2NT5EKRASSTING1FUT5 | |
| SCHEMBL401415 | 0.84 | TGM2 (0.56) | TGM2NT5EKRASSTING1FUT5 | |
| SCHEMBL23710659 | 0.83 | TGM2 (0.55) | TGM2NT5EKRASSTING1FUT5 | |
| SCHEMBL23710656 | 0.83 | TGM2 (0.55) | TGM2NT5EKRASSTING1FUT5 | |
| SCHEMBL6806886 | 0.83 | POLB (0.60) | TGM2NT5EKRASSTING1FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0671410-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-09-13 | — | — | EP | disclosed |
| US-5420115-A | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides | BURROUGHS WELLCOME CO. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |